2019 ASCO Annual Meeting!
Session: Melanoma/Skin Cancers
Type: Poster Session
Time: Monday June 3, 1:15 PM to 4:15 PM
Location: Hall A
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).
2019 ASCO Annual Meeting
Poster Board Number:
Poster Session (Board #139)
J Clin Oncol 37, 2019 (suppl; abstr 9568)
Author(s): Fiona Taylor, Meredith M. Regan, Dirk Schadendorf, Michael B. Atkins, Rachael Lawrance, Alejandro Moreno-Koehler, Andriy Moshyk, Sumati Rao, Corey Ritchings, SRIVIDYA KOTAPATI, Jennifer Lord-Bessen, Jasmine I. Rizzo, David F. McDermott, Mark R. Middleton; Adelphi Values, Boston, MA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Department of Dermatology, University of Essen, Essen, Germany; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Adelphi Values, Bollington, Cheshire, United Kingdom; Bristol Myers-Squibb, Princeton, NJ; Bristol-Myers Squibb, Princeton, NJ; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Department of Oncology, University of Oxford, Oxford, United Kingdom
Background: The TFI after discontinuation of study therapy has been reported to be longer with NIVO+IPI compared to NIVO or IPI alone, but QoL during the TFI has not been reported in advanced melanoma (MEL) studies. 1-y data from CheckMate (CM) 067 showed maintenance of QoL after treatment (tx) discontinuation with NIVO or NIVO+IPI. Here, we present long-term QoL results from CM 067 during the TFI (period off study tx and free of subsequent therapy), based on an updated 4-y dataset. Methods: In CM 067, 945 pts were randomized 1:1:1 to receive NIVO 3 mg/kg + placebo; NIVO 1 mg/kg + IPI 3 mg/kg × 4, then NIVO 3 mg/kg; or IPI 3 mg/kg × 4 + placebo. Patient-reported outcomes (PRO) were collected using the EORTC QLQ-C30 (5 functional domains, 9 symptoms, global health status) and EQ-5D-3L (utility index, visual analog scale) at baseline, on-tx visits, and follow-up (FU) visits 1 (FU1; 30 d after last dose) and 2 (FU2; 84 d after FU1). EQ-5D-3L was also collected at survival FU visits every 3 mo after FU2 in the first year and every 6 mo thereafter. Within the PRO analysis population, 480 of 764 pts who discontinued protocol tx (for any reason, including drug toxicity; n = 155) had PRO scores, collected prior to initiation of subsequent anticancer therapy, evaluated. Mean changes in PRO scores from last on-tx visit were reported for each FU visit. Results: Across tx arms, PRO scores were maintained from last on-tx visit to FU1 or FU2 for pts who discontinued for any reason. EORTC QLQ-C30 functional and symptom scales remained stable during the TFI. Among pts who discontinued tx due to toxicity, clinically meaningful deterioration in QoL was observed in a few subscales at FU1, but QoL was restored to the same level as the last on-tx visit in all except one subscale by FU2. PRO scores remained stable beyond FU2 for the EQ-5D-3L, regardless of reason for discontinuation. Data interpretation at later FU visits was limited due to smaller sample sizes. Sensitivity analyses for mean change in PRO scores from randomization to FU visits will be presented. Conclusions: QoL was maintained during the TFI, compared to last on-tx visit, in pts with MEL treated with NIVO or NIVO+IPI.